Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Jan;33(1):1–5. doi: 10.1128/aac.33.1.1

Mycobacteria and the new quinolones.

D C Leysen 1, A Haemers 1, S R Pattyn 1
PMCID: PMC171410  PMID: 2540705

Full text

PDF
4

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ball P. Ciprofloxacin: an overview of adverse experiences. J Antimicrob Chemother. 1986 Nov;18 (Suppl 500):187–193. doi: 10.1093/jac/18.sd.187. [DOI] [PubMed] [Google Scholar]
  2. Berlin O. G., Young L. S., Bruckner D. A. In-vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis. J Antimicrob Chemother. 1987 May;19(5):611–615. doi: 10.1093/jac/19.5.611. [DOI] [PubMed] [Google Scholar]
  3. Collins C. H., Uttley A. H. In-vitro susceptibility of mycobacteria to ciprofloxacin. J Antimicrob Chemother. 1985 Nov;16(5):575–580. doi: 10.1093/jac/16.5.575. [DOI] [PubMed] [Google Scholar]
  4. Collins C. H., Yates M. D., Uttley A. H. Differentiation of Mycobacterium chelonei from M. fortuitum by ciprofloxacin susceptibility. J Hyg (Lond) 1985 Dec;95(3):619–621. doi: 10.1017/s002217240006071x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dalhoff A., Eickenberg H. U. Tissue distribution of ciprofloxacin following oral and intravenous administration. Infection. 1985 Mar-Apr;13(2):78–81. doi: 10.1007/BF01660419. [DOI] [PubMed] [Google Scholar]
  6. Davidson P. T., Khanijo V., Goble M., Moulding T. S. Treatment of disease due to Mycobacterium intracellulare. Rev Infect Dis. 1981 Sep-Oct;3(5):1052–1059. doi: 10.1093/clinids/3.5.1052. [DOI] [PubMed] [Google Scholar]
  7. Davies B. I., Maesen F. P., Teengs J. P., Baur C. Neue orale Chinolon-Verbindungen bei chronischer Bronchitis. Infection. 1986;14 (Suppl 1):S73–S78. doi: 10.1007/BF01645205. [DOI] [PubMed] [Google Scholar]
  8. Davies S., Sparham P. D., Spencer R. C. Comparative in-vitro activity of five fluoroquinolones against mycobacteria. J Antimicrob Chemother. 1987 May;19(5):605–609. doi: 10.1093/jac/19.5.605. [DOI] [PubMed] [Google Scholar]
  9. Dutt A. K., Stead W. W. Long-term results of medical treatment in Mycobacterium intracellulare infection. Am J Med. 1979 Sep;67(3):449–453. doi: 10.1016/0002-9343(79)90792-7. [DOI] [PubMed] [Google Scholar]
  10. Düben W., Student A., Jablonski M., Malottke R. Zur Gewebekonzentration und Wirksamkeit von Ofloxacin bei chirurgischen Patienten. Infection. 1986;14 (Suppl 1):S70–S72. doi: 10.1007/BF01645204. [DOI] [PubMed] [Google Scholar]
  11. Easmon C. S., Crane J. P., Blowers A. Effect of ciprofloxacin on intracellular organisms: in-vitro and in-vivo studies. J Antimicrob Chemother. 1986 Nov;18 (Suppl 500):43–48. doi: 10.1093/jac/18.supplement_d.43. [DOI] [PubMed] [Google Scholar]
  12. Easmon C. S., Crane J. P. Uptake of ciprofloxacin by human neutrophils. J Antimicrob Chemother. 1985 Jul;16(1):67–73. doi: 10.1093/jac/16.1.67. [DOI] [PubMed] [Google Scholar]
  13. Easmon C., Verity L. Effect of Ro 23-6240 on sensitive and resistant intracellular mycobacteria. Eur J Clin Microbiol. 1987 Apr;6(2):165–166. doi: 10.1007/BF02018200. [DOI] [PubMed] [Google Scholar]
  14. Ernst F., van der Auwera P. In-vitro activity of fleroxacin (Ro 23-6240), a new fluoro-quinolone, and other agents, against Mycobacterium spp. J Antimicrob Chemother. 1988 Apr;21(4):501–504. doi: 10.1093/jac/21.4.501. [DOI] [PubMed] [Google Scholar]
  15. Fenlon C. H., Cynamon M. H. Comparative in vitro activities of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulare. Antimicrob Agents Chemother. 1986 Mar;29(3):386–388. doi: 10.1128/aac.29.3.386. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Fong I. W., Ledbetter W. H., Vandenbroucke A. C., Simbul M., Rahm V. Ciprofloxacin concentrations in bone and muscle after oral dosing. Antimicrob Agents Chemother. 1986 Mar;29(3):405–408. doi: 10.1128/aac.29.3.405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Fourtillan J. B., Granier J., Saint-Salvi B., Salmon J., Surjus A., Tremblay D., Vincent Du Laurier M., Beck S. Pharmacokinetics of ofloxacin and theophylline alone and in combination. Infection. 1986;14 (Suppl 1):S67–S69. doi: 10.1007/BF01645203. [DOI] [PubMed] [Google Scholar]
  18. Fur A., Massin F., Camus P., Waldner A., Jeannin L. Traitement de sauvetage d'une tuberculeuse pulmonaire multi-résistante. Efficacité de la péfloxacine. Presse Med. 1987 Jan 31;16(3):128–128. [PubMed] [Google Scholar]
  19. Gay J. D., DeYoung D. R., Roberts G. D. In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii. Antimicrob Agents Chemother. 1984 Jul;26(1):94–96. doi: 10.1128/aac.26.1.94. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Gaya H., Chadwick M. V. In vitro activity of ciprofloxacin against mycobacteria. Eur J Clin Microbiol. 1985 Jun;4(3):345–347. doi: 10.1007/BF02013668. [DOI] [PubMed] [Google Scholar]
  21. Goormans E., Dalhoff A., Kazzaz B., Branolte J. Penetration of ciprofloxacin into gynecological tissues following oral and intravenous administration. Chemotherapy. 1986;32(1):7–17. doi: 10.1159/000238383. [DOI] [PubMed] [Google Scholar]
  22. Guelpa-Lauras C. C., Perani E. G., Giroir A. M., Grosset J. H. Activities of pefloxacin and ciprofloxacin against Mycobacterium leprae in the mouse. Int J Lepr Other Mycobact Dis. 1987 Mar;55(1):70–77. [PubMed] [Google Scholar]
  23. Hohl P., Salfinger M., Kafader F. M. In vitro activity of the new quinolone RO 23-6240 (AM-833) and the new cephalosporins RO 15-8074 and RO 19-5247 (T-2525) against Mycobacterium fortuitum and Mycobacterium chelonae. Eur J Clin Microbiol. 1987 Aug;6(4):487–488. doi: 10.1007/BF02013118. [DOI] [PubMed] [Google Scholar]
  24. Horsburgh C. R., Jr, Mason U. G., 3rd, Farhi D. C., Iseman M. D. Disseminated infection with Mycobacterium avium-intracellulare. A report of 13 cases and a review of the literature. Medicine (Baltimore) 1985 Jan;64(1):36–48. doi: 10.1097/00005792-198501000-00003. [DOI] [PubMed] [Google Scholar]
  25. Ichiyama S., Tsukamura M. Ofloxacin and the treatment of pulmonary disease due to Mycobacterium fortuitum. Chest. 1987 Dec;92(6):1110–1112. doi: 10.1378/chest.92.6.1110. [DOI] [PubMed] [Google Scholar]
  26. Janknegt R. Fluorinated quinolones. A review of their mode of action, antimicrobial activity, pharmacokinetics and clinical efficacy. Pharm Weekbl Sci. 1986 Feb 21;8(1):1–21. doi: 10.1007/BF01975473. [DOI] [PubMed] [Google Scholar]
  27. Johnson S. M., Roberts G. D. In vitro activity of ciprofloxacin and ofloxacin against the Mycobacterium avium-intracellulare complex. Diagn Microbiol Infect Dis. 1987 May;7(1):89–91. doi: 10.1016/0732-8893(87)90077-0. [DOI] [PubMed] [Google Scholar]
  28. LeBel M., Vallée F., Bergeron M. G. Tissue penetration of ciprofloxacin after single and multiple doses. Antimicrob Agents Chemother. 1986 Mar;29(3):501–505. doi: 10.1128/aac.29.3.501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Lee K. [Superoxide anion (O2-) release from mouse peritoneal macrophages associated with ingestion of mycobacteria and effects of O2- on intracellular multiplication of mycobacteria]. Kekkaku. 1985 Jan;60(1):23–30. [PubMed] [Google Scholar]
  30. Licitra C. M., Brooks R. G., Sieger B. E. Clinical efficacy and levels of ciprofloxacin in tissue in patients with soft tissue infection. Antimicrob Agents Chemother. 1987 May;31(5):805–807. doi: 10.1128/aac.31.5.805. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Lockley M. R., Wise R., Dent J. The pharmacokinetics and tissue penetration of ofloxacin. J Antimicrob Chemother. 1984 Dec;14(6):647–652. doi: 10.1093/jac/14.6.647. [DOI] [PubMed] [Google Scholar]
  32. Maesen F. P., Davies B. I., Baur C., Sumajow C. A. Clinical, microbiological and pharmacokinetic studies on ofloxacin in acute purulent exacerbations of chronic respiratory disease. J Antimicrob Chemother. 1986 Nov;18(5):629–634. doi: 10.1093/jac/18.5.629. [DOI] [PubMed] [Google Scholar]
  33. Marinis E., Legakis N. J. In-vitro activity of ciprofloxacin against clinical isolates of mycobacteria resistant to antimycobacterial drugs. J Antimicrob Chemother. 1985 Oct;16(4):527–530. doi: 10.1093/jac/16.4.527. [DOI] [PubMed] [Google Scholar]
  34. Neuman M. Comparative pharmacokinetic parameters of new systemic fluoroquinolones. Int J Clin Pharmacol Res. 1987;7(3):173–179. [PubMed] [Google Scholar]
  35. Pattyn S. R., Van Caekenberghe D. L., Verhoeven J. R. In vitro activity of five new quinolones against cultivable mycobacteria. Eur J Clin Microbiol. 1987 Oct;6(5):572–573. doi: 10.1007/BF02014249. [DOI] [PubMed] [Google Scholar]
  36. Raoof S., Wollschlager C., Khan F. A. Ciprofloxacin increases serum levels of theophylline. Am J Med. 1987 Apr 27;82(4A):115–118. [PubMed] [Google Scholar]
  37. Rastogi N., Goh K. S., David H. L. Activity of five fluoroquinolones against Mycobacterium avium-intracellulare complex and M. xenopi. Ann Inst Pasteur Microbiol. 1988 Mar-Apr;139(2):233–237. doi: 10.1016/0769-2609(88)90008-7. [DOI] [PubMed] [Google Scholar]
  38. Rosenfeld M., Spannuth G., Wempe E., Kunz B., Bartels H., Visser K., Seydel J. K., Ruschmeyer H. J. In vitro activity of the new quinoline derivative ciprofloxacin alone and in combination against various Mycobacterium-, Salmonella- and Escherichia coli strains. Arzneimittelforschung. 1986 Jun;36(6):904–912. [PubMed] [Google Scholar]
  39. Rosenzweig D. Y. Pulmonary mycobacterial infections due to Mycobacterium intracellulare-avium complex. Clinical features and course in 100 consecutive cases. Chest. 1979 Feb;75(2):115–119. doi: 10.1378/chest.75.2.115. [DOI] [PubMed] [Google Scholar]
  40. Rubinstein E., Segev S. Drug interactions of ciprofloxacin with other non-antibiotic agents. Am J Med. 1987 Apr 27;82(4A):119–123. [PubMed] [Google Scholar]
  41. Saito H., Tomioka H., Nagashima K. In vitro and in vivo activities of ofloxacin against Mycobacterium leprae infection induced in mice. Int J Lepr Other Mycobact Dis. 1986 Dec;54(4):560–562. [PubMed] [Google Scholar]
  42. Sanders C. C., Sanders W. E., Jr, Goering R. V. Overview of preclinical studies with ciprofloxacin. Am J Med. 1987 Apr 27;82(4A):2–11. [PubMed] [Google Scholar]
  43. Smith M. J., White L. O., Bowyer H., Willis J., Hodson M. E., Batten J. C. Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis. Antimicrob Agents Chemother. 1986 Oct;30(4):614–616. doi: 10.1128/aac.30.4.614. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Steele L. C., Wallace R. J., Jr Ability of ciprofloxacin but not pipemidic acid to differentiate all three biovariants of Mycobacterium fortuitum from Mycobacterium chelonae. J Clin Microbiol. 1987 Feb;25(2):456–457. doi: 10.1128/jcm.25.2.456-457.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Swenson J. M., Wallace R. J., Jr, Silcox V. A., Thornsberry C. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother. 1985 Dec;28(6):807–811. doi: 10.1128/aac.28.6.807. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Texier-Maugein J., Mormède M., Fourche J., Bébéar C. In vitro activity of four fluoroquinolones against eighty-six isolates of mycobacteria. Eur J Clin Microbiol. 1987 Oct;6(5):584–586. doi: 10.1007/BF02014255. [DOI] [PubMed] [Google Scholar]
  47. Tsukamura M. Antituberculosis activity of ofloxacin (DL 8280) on experimental tuberculosis in mice. Am Rev Respir Dis. 1985 Oct;132(4):915–915. doi: 10.1164/arrd.1985.132.4.915. [DOI] [PubMed] [Google Scholar]
  48. Tsukamura M. Differentiation of Mycobacterium gordonae from Mycobacterium scrofulaceum and Mycobacterium szulgai by susceptibility to enoxacin (antimycobacterial activity of enoxacin). Microbiol Immunol. 1986;30(9):931–933. doi: 10.1111/j.1348-0421.1986.tb03022.x. [DOI] [PubMed] [Google Scholar]
  49. Tsukamura M. In vitro antimycobacterial activity of a new antibacterial substance DL-8280--differentiation between some species of mycobacteria and related organisms by the DL-8280 susceptibility test. Microbiol Immunol. 1983;27(12):1129–1132. doi: 10.1111/j.1348-0421.1983.tb02933.x. [DOI] [PubMed] [Google Scholar]
  50. Tsukamura M. In vitro antituberculosis activity of a new antibacterial substance ofloxacin (DL8280). Am Rev Respir Dis. 1985 Mar;131(3):348–351. doi: 10.1164/arrd.1985.131.3.348. [DOI] [PubMed] [Google Scholar]
  51. Tsukamura M., Kita N., Shimoide H., Yoshimoto K., Wada T., Mitani Y. [Lung infections due to Mycobacterium fortuitum and Mycobacterium chelonae. Reports of nine cases of M. fortuitum infection and four cases of M. chelonae infection]. Kekkaku. 1985 Aug;60(8):429–434. [PubMed] [Google Scholar]
  52. Tsukamura M., Mizuno S., Toyama H. [Comparison of in vitro growth-inhibitory activities of ofloxacin, ciprofloxacin and norfloxacin against various species of mycobacteria (comparison of organ concentrations and blood concentrations in mice)]. Kekkaku. 1986 Sep;61(9):453–459. [PubMed] [Google Scholar]
  53. Tsukamura M., Mizuno S. [Differentiation between mycobacterial species by the susceptibility test to ciprofloxacin--comparison of antimycobacterial spectra between ofloxacin and ciprofloxacin]. Kekkaku. 1986 Jun;61(6):357–359. [PubMed] [Google Scholar]
  54. Tsukamura M., Nakamura E., Yoshii S., Amano H. Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis. Am Rev Respir Dis. 1985 Mar;131(3):352–356. doi: 10.1164/arrd.1985.131.3.352. [DOI] [PubMed] [Google Scholar]
  55. Tsukamura M., Yoshii S., Yasuda Y., Saito H. [Antituberculosis chemotherapy including ofloxacin in patients with pulmonary tuberculosis not treated previously]. Kekkaku. 1986 Jan;61(1):15–17. [PubMed] [Google Scholar]
  56. Valero-Guillén P. L., Martín-Luengo F., Quintanilla I. In-vitro activity of some quinoline derivatives against Mycobacterium fortuitum. J Antimicrob Chemother. 1985 Feb;15(2):254–255. doi: 10.1093/jac/15.2.254. [DOI] [PubMed] [Google Scholar]
  57. Verho M., Dagrosa E. E., Malerczyk V. Klinische Pharmakologie von Ofloxacin: Ein neues Chemotherapeutikum aus der Reihe der Gyrasehemmer. Infection. 1986;14 (Suppl 1):S47–S53. doi: 10.1007/BF01645199. [DOI] [PubMed] [Google Scholar]
  58. Wise R., Donovan I. A. Tissue penetration and metabolism of ciprofloxacin. Am J Med. 1987 Apr 27;82(4A):103–107. [PubMed] [Google Scholar]
  59. Wise R., Lister D., McNulty C. A., Griggs D., Andrews J. M. The comparative pharmacokinetics of five quinolones. J Antimicrob Chemother. 1986 Nov;18 (Suppl 500):71–81. doi: 10.1093/jac/18.supplement_d.71. [DOI] [PubMed] [Google Scholar]
  60. Wolfson J. S., Hooper D. C. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother. 1985 Oct;28(4):581–586. doi: 10.1128/aac.28.4.581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Woods G. L., Hall G. S., Schreiber M. J. Mycobacterium fortuitum peritonitis associated with continuous ambulatory peritoneal dialysis. J Clin Microbiol. 1986 Apr;23(4):786–788. doi: 10.1128/jcm.23.4.786-788.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Yajko D. M., Nassos P. S., Hadley W. K. Therapeutic implications of inhibition versus killing of Mycobacterium avium complex by antimicrobial agents. Antimicrob Agents Chemother. 1987 Jan;31(1):117–120. doi: 10.1128/aac.31.1.117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Young L. S., Berlin O. G., Inderlied C. B. Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria. Am J Med. 1987 Apr 27;82(4A):23–26. [PubMed] [Google Scholar]
  64. Zimmer B. L., DeYoung D. R., Roberts G. D. In vitro synergistic activity of ethambutol, isoniazid, kanamycin, rifampin, and streptomycin against Mycobacterium avium-intracellulare complex. Antimicrob Agents Chemother. 1982 Jul;22(1):148–150. doi: 10.1128/aac.22.1.148. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. de Kantor I. N. Nuevas drogas activas contra el bacilo tuberculoso y otras micobacterias. Medicina (B Aires) 1986;46(1):107–112. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES